Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...
Investing.com -- Shares of Regulus Therapeutics (NASDAQ:RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...
Also Read: Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback